Abstract

In previously untreated RAS WT metastatic colorectal cancer, adding either cetuximab or panitumumab to chemotherapy produced benefits for patients, but neither was likely to be good value for money for the NHS.

Health Technology Assessment (HTA) publishes research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. Find out more about the HTA journal.